** Shares of Maryland-based vaccine maker Novavax NVAX.O up 1.6% at $7.44 premarket
** Company posts Q4 adj loss of 51 cents per share vs adj loss of $1.44 per share a year ago, as it ramps down spending on COVID vaccines, its only product on market
** Co signed a licensing deal worth at least $1.2 billion with French drugmaker SanofiSASY.PA in May to hand over the rights to sell its vaccines in several markets, including the U.S. and Europe
** NVAX reports quarterly sales of $88.3 million, beating analysts' avg estimate of $84.4 million - data compiled by LSEG
** Quarterly sales of COVID vaccines came in at $49.8 million, down 80.2% from a year earlier
** NVAX has risen 33% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.